CSBR — Champions Oncology, Inc.

Champions Oncology (CSBR) Q3 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $16.6 million, a decrease of 3% from $17 million in Q3 2025.
• Core Study Revenue: Reached a record $16.6 million, up 32% year-over-year from $12.6 million, reflecting strong execution and conversion of backlog.
• Data Revenue: No revenue recognized this quarter from the data platform, down from $4.5 million in the prior year.
• Adjusted EBITDA: Positive for the third consecutive quarter at $575,000; GAAP loss from operations was approximately $275,000.
• Gross Margin: 47%, down from 61% year-over-year, impacted by increased costs from outsourced laboratory work.
• Operating Expenses: Increased to $7.2 million from $5.3 million, reflecting strategic investments.
• Cash Position: Ended the quarter with $7.1 million in cash and no debt.

2. Strategic Updates and Business Highlights

• Continued strong performance in core translational oncology services, with a focus on expanding the services pipeline through increased commercial engagement.
• Early momentum in the data business, with a six-figure deal closed expected to contribute revenue in Q4.
• Corellia, the target discovery subsidiary, is generating positive feedback and is included in fiscal 2027 budgeting, with potential for external funding.
• Emphasis on maintaining positive adjusted EBITDA while investing in growth initiatives without diluting shares.

3. Forward Guidance and Outlook

• Expectation of full-year revenue growth and positive adjusted EBITDA for fiscal 2026.
• Anticipation of normalization in revenue as study phases progress, but underlying demand for services remains strong.
• Investments made in Q3 are expected to yield results in fiscal 2027, with more significant growth anticipated in fiscal 2028.

4. Bad News, Challenges, or Points of Concern

• Year-over-year revenue decline attributed to the absence of data revenue this quarter, which is expected to vary significantly as the platform develops.
• Gross margin pressure due to increased costs associated with outsourced laboratory work, although internalizing these processes is expected to improve margins over time.
• Operating expenses have risen due to investments in R&D and sales/marketing, which may impact short-term profitability.

5. Notable Q&A Insights

• There were no questions from analysts during the call, indicating a lack of immediate concerns or inquiries from the investment community.
• CEO Rob Brainin reiterated the company's commitment to balancing growth and investment while maintaining positive adjusted EBITDA.

Overall, Champions Oncology reported a solid quarter with record services revenue and positive adjusted EBITDA, while also navigating challenges related to the data platform's revenue generation and rising operating costs. The company remains optimistic about future growth driven by strategic investments and a strong demand for its services.